BioAtla (BCAB) said Monday its cancer therapy BA3182 showed "encouraging preliminary prolonged tumor control" in a first-in-human phase 1 study.
The therapy targets a tumor cell often present in adenocarcinomas of the colon, stomach, pancreas, biliary tract, lung, breast, prostate, and thyroid, the company said.
Chief Executive Jay M. Short also said the therapy showed "a manageable safety profile" in the 35-patient study.
Shares of the company were down 13% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.